CoChat

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation

Open access
Teoh, Phaik Ju, Bi, Chonglei, Sintosebastian, Chirackal, Tay, Liang Seah, Fonseca, Rafael, Chng, Wee Joo · 2016 · Oncotarget
Cited by 28

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

// Phaik Ju Teoh 1, 4 , Chonglei Bi 1 , Chirackal Sintosebastian 2 , Liang Seah Tay 3 , Rafael Fonseca 2 , Wee Joo Chng 1, 2, 4 1 Cancer Science Institute Singapore, National University of Singapore, Singapore 2 Department of Hematology-Oncology, Mayo Clinic, Scottsdale, Arizona, USA 3 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 4 Department of Haematology-Oncology, National University Cancer Institute, Singapore Correspondence to: Wee Joo Chng, email: csicwj@nus.edu.sg Keywords: multiple myeloma, PRIMA-1, ER stress, p73, bortezomib Received: May 05, 2016 Accepted: July 28, 2016 Published: August 12, 2016 ABSTRACT Despite therapeutic advancement, multiple myeloma (MM) remains incurable with drug resistance being one of the main challenges in the clinic. Myeloma cells possess high protein secretory load, leading to increased intracellular endoplasmic reticulum (ER) stress. Hence, they are vulnerable to further perturbation to its protein homeostasis. In studying the therapeutic mechanism of PRIMA-1 (mutant-p53-reactivating-agent), we uncovered its novel p53-independent-mechanism that can be exploited for myeloma. Despite its inability in restoring the wild type-p53 protein conformation and transcriptional function in the mutant-p53-human-myeloma-cells, PRIMA-1 was efficacious against myeloma cells with differential p53 genotypes. Strikingly, cells without p53 expression demonstrated highest drug sensitivity. Genome-wide gene-expression analysis revealed the involvement of ER stress/UPR-pathway in inducing PRIMA-1-toxicity. UPR markers, HSP70, CHOP and GADD34, were significantly up-regulated, concomitantly with the induction of apoptosis. Furthermore, there was a global attenuation of protein synthesis, correlated with phospho-eIF2a up-regulation. Mechanistically, we identified that PRIMA-1 could cause the demethylation of TP73 , through DNMT1 depletion, to subsequently enhance UPR. Of clinical significance, we observed that PRIMA-1 had additive therapeutic effects with another UPR-inducing-agent, bortezomib. Importantly, it can partially re-sensitize bortezomib-resistant cells to bortezomib. Given that MM is already stressed at the baseline in the ER, our results implicated that PRIMA-1 is a potential therapeutic option in MM by targeting its Achilles heel.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11241

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 28

Metadata

Authors
Teoh, P. J., Bi, C., Sintosebastian, C., Tay, L. S., Fonseca, R., & Chng, W. J.
Venue
Oncotarget
Published
2016-08-12
Volume
7
Issue
38
Pages
61806-61819
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2514741988
Cited by
28
References
10
FWCI
3.69
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. https://app.cochat.ai/papers/10.18632/oncotarget.11241
The paper
Teoh, P. J., Bi, C., Sintosebastian, C., Tay, L. S., Fonseca, R., & Chng, W. J. (2016). PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget. https://doi.org/10.18632/oncotarget.11241

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.